Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
- PMID: 16847145
- DOI: 10.1124/mol.106.022624
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
Abstract
The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP). Wild-type murine embryonic fibroblasts (CTR1+/+) and a subline in which both alleles of CTR1 were deleted (CTR1-/-) were tested for their ability to accumulate platinum when exposed to increasing concentrations of DDP, CBDCA, or L-OHP for 1 h. They were also tested for their sensitivity to the growth-inhibitory effect of each drug. Platinum content was measured by ion-coupled plasmon mass spectroscopy. The experimental model was validated by measuring copper accumulation and cytotoxicity. CTR1-/- cells accumulated only 5.7% as much copper as CTR1+/+ cells during a 1-h exposure to 2 microM copper. When exposed to DDP, CBDCA, or L-OHP at 2 microM, accumulation in the CTR1-/- cells was only 35 to 36% of that in the CTR1+/+ cells. When tested at a 5-fold higher concentration, this deficit remained for DDP and CBDCA, but accumulation of L-OHP was no longer CTR1-dependent. There was an association between the effect of loss of CTR1 function on uptake of the platinum drugs and their cytotoxicity. The CTR1-/- cells were 3.2-fold resistant to DDP, 2.0-fold resistant to CBDCA, but only 1.7-fold resistant to L-OHP. Thus, whereas CTR1 controls the cellular accumulation of all three drugs at low concentrations, accumulation of L-OHP is not dependent on CTR1 at higher concentrations. We conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clinical spectrum of activity.
Similar articles
-
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.Cancer Chemother Pharmacol. 2006 Jun;57(6):781-8. doi: 10.1007/s00280-005-0121-5. Epub 2005 Sep 17. Cancer Chemother Pharmacol. 2006. PMID: 16170571
-
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.Mol Pharmacol. 2009 Feb;75(2):324-30. doi: 10.1124/mol.108.052381. Epub 2008 Nov 7. Mol Pharmacol. 2009. PMID: 18996970 Free PMC article.
-
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.Mol Pharmacol. 2004 Oct;66(4):817-23. doi: 10.1124/mol.104.001198. Epub 2004 Jun 30. Mol Pharmacol. 2004. PMID: 15229296
-
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.Mol Pharmacol. 2010 Jun;77(6):887-94. doi: 10.1124/mol.109.063172. Epub 2010 Feb 16. Mol Pharmacol. 2010. PMID: 20159940 Free PMC article. Review.
-
Role of copper transporters in the uptake and efflux of platinum containing drugs.Cancer Lett. 2006 Mar 8;234(1):34-9. doi: 10.1016/j.canlet.2005.07.046. Epub 2005 Nov 16. Cancer Lett. 2006. PMID: 16297532 Review.
Cited by
-
Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.Expert Opin Ther Targets. 2015;19(10):1307-17. doi: 10.1517/14728222.2015.1043269. Epub 2015 May 25. Expert Opin Ther Targets. 2015. PMID: 26004625 Free PMC article. Review.
-
Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.Med Oncol. 2023 Dec 8;41(1):9. doi: 10.1007/s12032-023-02237-w. Med Oncol. 2023. PMID: 38063931 Review.
-
Mammalian copper homeostasis requires retromer-dependent recycling of the high-affinity copper transporter 1.J Cell Sci. 2020 Aug 25;133(16):jcs249201. doi: 10.1242/jcs.249201. J Cell Sci. 2020. PMID: 32843536 Free PMC article.
-
Role of transporters in the distribution of platinum-based drugs.Front Pharmacol. 2015 Apr 24;6:85. doi: 10.3389/fphar.2015.00085. eCollection 2015. Front Pharmacol. 2015. PMID: 25964760 Free PMC article. Review.
-
Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.Mol Pharmacol. 2011 Jan;79(1):157-66. doi: 10.1124/mol.110.068411. Epub 2010 Oct 7. Mol Pharmacol. 2011. PMID: 20930109 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials